Systemic administration of alkylphosphocholines. Erucylphosphocholine and liposomal hexadecylphosphocholine.
Kaufmann-Kolle
P
P
Max-Planck-Institut für biophysikalische Chemie, Am Fassberg, Göttingen, Germany.
Berger
M R
MR
Unger
C
C
Eibl
H
H
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D019540:Area Under Curve; D006207:Half-Life; D007275:Injections, Intravenous; D008081:Liposomes; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy; D010767:Phosphorylcholine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D008081:Liposomes; D010767:Phosphorylcholine; C075010:erucylphosphocholine; C039128:miltefosine